Dyadic Announces Strategic Partnership Agreement To Develop Affordable Rabies Prophylactics And Vaccines Using Its C1 Cell Microbial Protein Production Platform
Portfolio Pulse from Benzinga Newsdesk
Dyadic International, Inc. (NASDAQ:DYAI) has announced a strategic partnership with Rabian BV to develop affordable rabies vaccines using its C1 protein production platform. The collaboration, supported by Eurostars and the European Union's Horizon Europe, aims to address the global rabies burden, particularly in lower- and middle-income countries. Dyadic will receive an equity stake, fully funded R&D costs, and royalties upon commercialization. This partnership builds on a long-standing collaboration between the two entities, focusing on making preventive vaccination more accessible and cost-effective.
February 28, 2024 | 1:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dyadic International, Inc. enters a strategic partnership with Rabian BV to develop affordable rabies vaccines, leveraging its C1 platform. The deal includes equity, funded R&D, and future royalties, aiming to address rabies in lower-income countries.
The partnership with Rabian BV represents a significant step for Dyadic in applying its C1 protein production platform towards addressing a critical global health issue. The financial terms, including equity, funded R&D, and future royalties, suggest a strong commitment and potential revenue stream upon commercialization. Given the global burden of rabies and the focus on lower- and middle-income countries, this partnership could enhance Dyadic's market position and reputation in the biotech and vaccine development sector.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100